Therapeutic issues in Guillain–Barré syndrome

References

• Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214–1228.
   PubMed Web of Science ®Google Scholar
• Asbury AK, Arnason BGW, et al. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978;3:565–566.
   PubMedGoogle Scholar
• Asbury AK. Guillain‐barré syndrome: historical aspects. Ann Neurol. 1990;27(S1):S2–6.
   PubMedGoogle Scholar
• Doets AY, Verboon C, van den BB, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866–2877. DOI:10.1093/brain/awy232
   PubMed Web of Science ®Google Scholar
• Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide cérébrospinal sans réaction cellulaire: remarques sur les caractères cliniques et graphiques des réflexes tendineux. Bulletins et mémoires de la Société des Médecins des Hôpitaux de Paris. 1916;40:1462–1470.
   Google Scholar
• Prineas JW. Pathology of the Guillain‐Barré syndrome. Ann Neurol. 1981;9(S1):6–19.
   PubMed Web of Science ®Google Scholar
• Feasby TE, Gilbert JJ, Brown WF, et al. Acute “axonal” Guillain-Barre polyneuropathy. Neurology. 1987;37(2):357. DOI:10.1212/WNL.37.2.357-b
   PubMed Web of Science ®Google Scholar
• Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Medicine. 1993;178(5):1771–1775. DOI:10.1084/jem.178.5.1771
   PubMed Web of Science ®Google Scholar
• Griffin JW, Li CY, Ho TW, et al. Guillain-Barré syndrome in northern China: the spectrum of neuropathological changes in clinically defined cases. Brain. 1995;118(3):577–595. DOI:10.1093/brain/118.3.577
   PubMedGoogle Scholar
• van der MF, Schmitz PIM. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barré syndrome. New Engl J Medicine. 1992;326(17):1123–1129.
   PubMed Web of Science ®Google Scholar
• Cao-Lormeau V-M, Blake A, Mons S, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–1539. DOI:10.1016/S0140-6736(16)00562-6
   PubMed Web of Science ®Google Scholar
• Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2020;144:awaa433.
   Web of Science ®Google Scholar
• Querol L, Lleixà C. Novel immunological and therapeutic insights in Guillain-Barré Syndrome and CIDP. Neurotherapeutics. 2021;18(4):2222–2235.
   PubMed Web of Science ®Google Scholar
• Wakerley BR, Uncini A, Yuki N, et al. Guillain–barré and Miller Fisher syndromes—new diagnostic classification. Nat Rev Neurol. 2014;10(9):537–544. DOI:10.1038/nrneurol.2014.138
   PubMed Web of Science ®Google Scholar
• Albertí MA, Alentorn A, Martínez‐yelamos S, et al. Very early electrodiagnostic findings in Guillain‐Barré syndrome. J Peripher Nerv Syst. 2011;16(2):136–142. DOI:10.1111/j.1529-8027.2011.00338.x
   PubMed Web of Science ®Google Scholar
• Meulstee J, van der MF. Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. J Neurology Neurosurg Psychiatry. 1995;59(5):482.
   PubMed Web of Science ®Google Scholar
• Vucic S, Cairns KD, Black KR, et al. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol. 2004;115(10):2329–2335. DOI:10.1016/j.clinph.2004.05.009
   PubMed Web of Science ®Google Scholar
• Veltsista D, Kefalopoulou Z, Kintos V, et al. Identical late motor responses in early Guillain‐Barré syndrome: a‐waves and repeater F‐waves. J Peripher Nerv Syst. 2023;28(1):41–46. DOI:10.1111/jns.12522
   PubMed Web of Science ®Google Scholar
• Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain‐Barré syndrome. Ann Neurol. 1990;27(S1):S21–24.
   PubMedGoogle Scholar
• Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain–barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3):599–612. DOI:10.1016/j.vaccine.2010.06.003
   PubMed Web of Science ®Google Scholar
• Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110(2):105–123. DOI:10.1093/oxfordjournals.aje.a112795
   PubMed Web of Science ®Google Scholar
• Salmon DA, Proschan M, Forshee R, et al. Association between Guillain-Barré syndrome and influenza a (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013;381(9876):1461–1468. DOI:10.1016/S0140-6736(12)62189-8
   PubMed Web of Science ®Google Scholar
• Lehmann HC, Hartung H-P, Kieseier BC, et al. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 2010;10(9):643–651. DOI:10.1016/S1473-3099(10)70140-7
   PubMed Web of Science ®Google Scholar
• Hafer‐macko C, Hsieh S, Ho TW, et al. Acute motor axonal neuropathy: an antibody‐mediated attack on axolemma. Ann Neurol. 1996;40(4):635–644. DOI:10.1002/ana.410400414
   PubMed Web of Science ®Google Scholar
• Hafer‐macko CE, Sheikh KA, Li CY, et al. Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39(5):625–635. DOI:10.1002/ana.410390512
   PubMed Web of Science ®Google Scholar
• Haymaker W, Kernohan JW. The Landry-Guillain-Barré Syndrome. Medicine. 1949;28(1):59.
   PubMed Web of Science ®Google Scholar
• McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33(4):333–342. DOI:10.1002/ana.410330402
   PubMed Web of Science ®Google Scholar
• Berciano J, Gallardo E, Orizaola P, et al. Early axonal Guillain-Barré syndrome with normal peripheral conduction: imaging evidence for changes in proximal nerve segments. J Neurology Neurosurg Psychiatry. 2016;87(5):563. DOI:10.1136/jnnp-2015-310601
   PubMed Web of Science ®Google Scholar
• Wanschitz J, Maier H, Lassmann H, et al. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain–Barré syndrome. Brain. 2003;126(9):2034–2042. DOI:10.1093/brain/awg207
   PubMedGoogle Scholar
• Kusunoki S, Willison HJ, Jacobs BC. Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective. J Neurology Neurosurg Psychiatry. 2020;92(3): jnnp-2020-325053. DOI:10.1136/jnnp-2020-325053.
   Web of Science ®Google Scholar
• Chan Y, Punzalan‐sotelo AM, Kannan TA, et al. Electrodiagnosis of reversible conduction failure in Guillain–Barré syndrome. Muscle Nerve. 2017;56(5):919–924. DOI:10.1002/mus.25577
   PubMed Web of Science ®Google Scholar
• Yuki N, Yoshino H, Sato S, et al. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology. 1990;40(12):1900. DOI:10.1212/WNL.40.12.1900
   PubMed Web of Science ®Google Scholar
• Papri N, Islam Z, Leonhard SE, et al. Guillain–barré syndrome in low-income and middle-income countries: challenges and prospects. Nat Rev Neurol. 2021;17(5):285–296. DOI:10.1038/s41582-021-00467-y
   PubMed Web of Science ®Google Scholar
• Hiraga A, Mori M, Ogawara K, et al. Recovery patterns and long term prognosis for axonal Guillain–Barré syndrome. J Neurology Neurosurg Psychiatry. 2005;76(5):719. DOI:10.1136/jnnp.2004.051136
   PubMed Web of Science ®Google Scholar
• Ye Y, Wang K, Deng F, et al. Electrophysiological subtypes and prognosis of Guillain-Barré syndrome in Northeastern China. Muscle Nerve. 2013;47(1):68–71. DOI:10.1002/mus.23477
   PubMed Web of Science ®Google Scholar
• The Italian Guillain-Barré Study Group, Hughes RA, Hadden RD, et al. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. Brain. 1998;121(4):767–769.
   PubMedGoogle Scholar
• Chiò A, Cocito D, Leone M, et al. Guillain-Barré syndrome. Neurology. 2003;60(7):1146–1150. DOI:10.1212/01.WNL.0000055091.96905.D0
   PubMed Web of Science ®Google Scholar
• van KR, Steyerberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 2007;6(7):589–594. DOI:10.1016/S1474-4422(07)70130-8
   PubMed Web of Science ®Google Scholar
• Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain-Barré syndrome(Podcast). Neurology. 2011;76(11):968–975. DOI:10.1212/WNL.0b013e3182104407
   PubMed Web of Science ®Google Scholar
• Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain‐Barré syndrome. Ann Neurol. 2010;67:781–787.
   PubMed Web of Science ®Google Scholar
• Luijten LWG, Doets AY, Arends S, et al. Modified Erasmus GBS respiratory insufficiency score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barré syndrome. J Neurology Neurosurg Psychiatry. 2022;94(4):300–308. jnnp-2022-329937. DOI:10.1136/jnnp-2022-329937
   PubMed Web of Science ®Google Scholar
• Fokkink WJ, Walgaard C, Kuitwaard K, et al. Association of albumin levels with outcome in Intravenous Immunoglobulin–Treated Guillain-Barré Syndrome. JAMA Neurol. 2016;74(2):189. DOI:10.1001/jamaneurol.2016.4480
   Web of Science ®Google Scholar
• Martín-Aguilar L, Camps-Renom P, Lleixà C, et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. J Neurology Neurosurg Psychiatry. 2021;92(1):70–77. DOI:10.1136/jnnp-2020-323899
   Web of Science ®Google Scholar
• Kuitwaard K, de GJ, Tio‐gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol. 2009;66(5):597–603. DOI:10.1002/ana.21737
   PubMed Web of Science ®Google Scholar
• Min YG, Ju W, Seo J-W, et al. Serum C3 complement levels predict prognosis and monitor disease activity in Guillain-Barré syndrome. J Neurol Sci. 2023;444:120512.
   PubMed Web of Science ®Google Scholar
• Martinez V, Fletcher D, Martin F, et al. Small fibre impairment predicts neuropathic pain in Guillain–Barré syndrome. Pain. 2010;151(1):53–60. DOI:10.1016/j.pain.2010.05.017
   PubMed Web of Science ®Google Scholar
• Ruts L, Drenthen J, Jongen JLM, et al. Pain in Guillain-Barré syndrome. Neurology. 2010;75(16):1439–1447. DOI:10.1212/WNL.0b013e3181f88345
   PubMed Web of Science ®Google Scholar
• Merkies ISJ, Kieseier BC. Fatigue, Pain, Anxiety and Depression in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Eur Neurol. 2016;75(3–4):199–206.
   PubMed Web of Science ®Google Scholar
• Brettle RP, Gross M, Legg NJ, et al. Treatment of acute polyneuropathy by plasma exchange. Lancet. 1978;312(8099):1100. DOI:10.1016/S0140-6736(78)91837-8
   Google Scholar
• Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987;22(6):753–761. DOI:10.1002/ana.410220612
   PubMed Web of Science ®Google Scholar
• McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and guillain‐barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988;23(4):347–353. DOI:10.1002/ana.410230406
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Wijdicks EFM, Barohn R, et al. Practice parameter: immunotherapy for Guillain–Barré syndrome. Neurology. 2003;61(6):736–740. DOI:10.1212/WNL.61.6.736
   PubMed Web of Science ®Google Scholar
• Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol. 1997;41(3):298–306. DOI:10.1002/ana.410410304
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol. 2013;12(12):1180–1188.
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. New Engl J Medicine. 2012;367(21):2015–2025.
   PubMed Web of Science ®Google Scholar
• Kleyweg RP, van der MF, Meulstee J. Treatment of Guillain-Barre syndrome with high-dose gammaglobulin. Neurology. 1988;38(10):1639.
   PubMed Web of Science ®Google Scholar
• Hughes RA, Swan AV, van DP. Intravenous immunoglobulin for Guillain‐Barré syndrome. Cochrane Db Syst Rev. 2014;2019(10): CD002063. DOI:10.1002/14651858.CD002063.pub6.
   Google Scholar
• Kalita J, Misra UK, Chaudhary SK, et al. Outcome of Guillain–Barré syndrome following intravenous immunoglobulin compared to natural course. Eur J Neurol. 2022;29(10):3071–3080. DOI:10.1111/ene.15500
   PubMed Web of Science ®Google Scholar
• Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet Lond Engl. 1997;349(9047):225–230. DOI:10.1016/S0140-6736(96)09095-2
   Google Scholar
• Imbach P, d’Apuzzo V, Hirt A, et al. HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN for IDIOPATHIC THROMBOCYTOPENIC PURPURA in CHILDHOOD. Lancet. 1981;317(8232):1228–1231. DOI:10.1016/S0140-6736(81)92400-4
   Google Scholar
• Raphael JC, Chevret S, Harboun M, et al. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurology Neurosurg Psychiatry. 2001;71(2):235. DOI:10.1136/jnnp.71.2.235
   PubMed Web of Science ®Google Scholar
• Walgaard C, Jacobs BC, Lingsma HF, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(4):275–283. DOI:10.1016/S1474-4422(20)30494-4
   PubMed Web of Science ®Google Scholar
• Verboon C, van den BB, Cornblath DR, et al. Original research: second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. J Neurology Neurosurg Psychiatry. 2020;91(2):113. DOI:10.1136/jnnp-2019-321496
   PubMed Web of Science ®Google Scholar
• Verboon C, van DP, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. J Neurology Neurosurg Psychiatry. 2017;88(4):346.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, O’Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11(2):136–141. DOI:10.1002/ana.410110205
   PubMed Web of Science ®Google Scholar
• Hughes RA, Mehndiratta MM, Rajabally YA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Db Syst Rev. 2017;2019(10): CD002062. DOI:10.1002/14651858.CD002062.pub4.
   Google Scholar
• Fargeot G, Gitiaux C, Magy L, et al. French recommendations for the management of adult & pediatric chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Rev Neurol. 2022;178(9):953–968. DOI:10.1016/j.neurol.2022.06.004
   PubMedGoogle Scholar
• den BP, Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force — Second Revision. J Peripher Nerv Syst. 2021.
   Google Scholar
• Watts PM, Taylor WA, Hughes RAC. High-dose methylprednisolone suppresses experimental allergic neuritis in the Lewis rat. Exp Neurol. 1989;103(1):101–104.
   PubMed Web of Science ®Google Scholar
• Hughes RA, Brassington R, Gunn AA, et al. Corticosteroids for Guillain‐Barré syndrome. Cochrane Db Syst Rev. 2016;2016(10): CD001446. DOI:10.1002/14651858.CD001446.pub5
   Google Scholar
• Rich MM, Pinter MJ, Kraner SD, et al. Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol. 1998;43(2):171–179. DOI:10.1002/ana.410430207
   PubMed Web of Science ®Google Scholar
• Ma L, Liu S, Xiao Z, et al. Comparison of the effects of different doses of Glucocorticoids on distinct subtypes of Guillain-Barré syndrome in Southern China. BMC neurol. 2022;22(1):46. DOI:10.1186/s12883-022-02567-8
   PubMed Web of Science ®Google Scholar
• Moulin DE, Hagen N, Feasby TE, et al. Pain in Guillain-Barre syndrome. Neurology. 1997;48(2):328–331. DOI:10.1212/WNL.48.2.328
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, McNicol ED. Pharmacological treatment for pain in Guillain‐Barré syndrome. Cochrane Db Syst Rev. 2015;2019(2): CD009950. DOI:10.1002/14651858.CD009950.pub3.
   Google Scholar
• Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256–1264. DOI:10.1038/nbt1344
   PubMed Web of Science ®Google Scholar
• Halstead SK, Zitman FMP, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131(5):1197–1208. DOI:10.1093/brain/awm316
   PubMedGoogle Scholar
• Davidson AI, Halstead SK, Goodfellow JA, et al. Inhibition of complement in Guillain‐Barré syndrome: the ICA‐GBS study. J Peripher Nerv Syst. 2017;22(1):4–12. DOI:10.1111/jns.12194
   PubMed Web of Science ®Google Scholar
• Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17(6):519–529. DOI:10.1016/S1474-4422(18)30114-5
   PubMed Web of Science ®Google Scholar
• Lansita JA, Mease KM, Qiu H, et al. Nonclinical Development of ANX005: a Humanized Anti-C1q Antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol. 2017;36(6):449–462. DOI:10.1177/1091581817740873
   PubMed Web of Science ®Google Scholar
• McGonigal R, Cunningham ME, Yao D, et al. C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy. Acta Neuropathologica Commun. 2016;4(1):23. DOI:10.1186/s40478-016-0291-x
   PubMedGoogle Scholar
• Papri N, Islam Z, Jahan I, et al. ANX005, a C1q inhibitor, for treatment of Guillain-Barré Syndrome: Phase 1b study results. Poster 207. 2020 peripheral nerve society virtual event. J Peripher Nerv Syst. 2020;25:438–576.
   Google Scholar
• Azad KAK, Allen JA, Habib M, et al. Effect of ANX005 on MRC sum score and patient prognosis: From GBS-01 Phase 1b study. Poster 204. 2020 peripheral nerve society virtual event. J Peripher Nerv Syst. 2020;25:438–576.
   Google Scholar
• Al-Salama ZT. Imlifidase: first Approval. Drugs. 2020;80(17):1859–1864.
   PubMed Web of Science ®Google Scholar
• Winstedt L, Järnum S, Nordahl EA, et al. Complete removal of extracellular igg antibodies in a randomized dose-escalation phase i study with the bacterial enzyme ides – a novel therapeutic opportunity. PLoS ONE. 2015;10(7):e0132011. DOI:10.1371/journal.pone.0132011
   PubMed Web of Science ®Google Scholar
• JS C, Tomas L, Jua C, et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. NEW ENGL J MED. 2017;377(5):442–453. DOI:10.1056/NEJMoa1612567
   PubMed Web of Science ®Google Scholar
• Doets AY, Hughes RA, Brassington R, et al. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain‐Barré syndrome. Cochrane Db Syst Rev. 2020;2020(1): CD008630. DOI:10.1002/14651858.CD008630.pub5
   Google Scholar
• Zhang X, Xia J, Ye H. Effect of Tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barre syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi Chin J Integr Traditional West Medicine. 2000;20:332–334.
   PubMedGoogle Scholar
• MPJ G, van KR, van DP, et al. Treatment of Guillain–Barré syndrome with mycophenolate mofetil: a pilot study. J Neurology Neurosurg Psychiatry. 2007;78(9):1012. DOI:10.1136/jnnp.2006.102731
   PubMed Web of Science ®Google Scholar
• Bensa S, Hadden RDM, Hahn A, et al. Randomized controlled trial of brain‐derived neurotrophic factor in Guillain–Barré syndrome: a pilot study. Eur J Neurol. 2000;7:423–426.
   PubMed Web of Science ®Google Scholar
• Pritchard J, Gray IA, Idrissova ZR, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology. 2003;61(9):1282–1284. DOI:10.1212/01.WNL.0000092019.53628.88
   PubMed Web of Science ®Google Scholar
• Kokubun N, Nishibayashi M, Uncini A, et al. Conduction block in acute motor axonal neuropathy. Brain. 2010;133(10):2897–2908. DOI:10.1093/brain/awq260
   PubMedGoogle Scholar